Active Substance: Deferiprone.
Overview
Welcome to Dwaey, specifically on FERRIPROX 500mg page.
This medicine contains an important and useful components, as it consists of
Deferiproneis available in the market in concentration
Deferiprone
Hepatic and renal impairment. Neutropenia, monitor neutrophil count wkly and discontinue treatment if neutropenia develops. Limited experience in children 6-10 yr. Lactation: Unknown whether distributed in breast milk; because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
Thalassaemia,Iron overload
Agranulocytosis, pregnancy and lactation.
>10% Chromaturia (14.6%),Nausea (12.6%),Abdominal pain/discomfort (10.4%) 1-10% Arthralgia (9.8%),Vomiting (9.8%),Increased ALT (7.5%),Decreased neutrophil count (7.3%),Neutropenia (6.2%),Increased appetite (4%),Diarrhea (3%),Headache (2.5%),Dyspepsia (2%),Back pain (2%),Extremity pain (1.9%),Increased weight (1.9%),Agranulocytosis (1.7%),Arthropathy (1.4%),Increased AST (1.2%),Decreased appetite (1.1%)
4
Deferiprone is an orally effective iron-chelating agent. It is being used when desferrioxamine is unsuitable or contraindicated.
Avoid using deferiprone with aluminium-containing antacids as it can chelates trivalent metal ions.
Information not available